JOSE CARLOS
ARMARIO HITA
Profesor Titular de Universidad
Hospital Universitario San Cecilio
Granada, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario San Cecilio (31)
2024
-
Standard and Expanded Series Patch Testing Update by the Spanish Contact Dermatitis and Skin Allergy Research Group (GEIDAC)
Actas Dermo-Sifiliograficas
-
[Translated article] Efficacy and Pharmacoeconomic Analysis in Real Clinical Practice Conditions of Patients with Plaque Psoriasis Treated with Guselkumab: A Retrospective Multicenter Study
Actas Dermo-Sifiliograficas
2023
-
Brodalumab: Efficacy, safety, and survival in mid-term (52 weeks) on real clinical practice in Andalucia, Spain
International Journal of Dermatology, Vol. 62, Núm. 5, pp. 700-706
-
Clinical Approach to Patients with Moderate-to-Severe Atopic Dermatitis: A Spanish Delphi Consensus
Acta Dermato-Venereologica, Vol. 103
-
Efficacy and Pharmacoeconomic Analysis in Real Clinical Practice Conditions of Patients with Plaque Psoriasis Treated with Guselkumab: A Retrospective Multicenter Study
Actas Dermo-Sifiliograficas
-
Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness and safety results
Clinical and experimental dermatology, Vol. 48, Núm. 9, pp. 991-997
-
Upadacitinib for moderate to severe atopic dermatitis
Immunotherapy, Vol. 15, Núm. 11, pp. 799-808
-
Updated Review on Treatment of Atopic Dermatitis
Journal of Investigational Allergology and Clinical Immunology, Vol. 33, Núm. 3, pp. 158-167
2022
-
Atopic Dermatitis: Background, Objectives and Future Perspectives (Superresponders)
Life
-
Effectiveness, survival and safety of guselkumab attending to basal characteristics in moderate-to-severe psoriatic patients: A cohort study
F1000Research, Vol. 11
-
Guselkumab as a switching strategy after anti-TNFα, anti-IL17, or anti-IL12/23 therapies in moderate-to-severe psoriasis
Dermatologic Therapy, Vol. 35, Núm. 10
-
Guselkumab dosing interval optimization in adult patients with moderate-to-severe psoriasis switching from ustekinumab
Dermatologic Therapy, Vol. 35, Núm. 11
-
Long-Term Effectiveness and Safety of Biologic and Small Molecule Drugs for Moderate to Severe Atopic Dermatitis: A Systematic Review
Life, Vol. 12, Núm. 8
-
Optimising the Therapeutic Interval for Biologics in Patients with Psoriasis
Life, Vol. 12, Núm. 12
-
Super responders to guselkumab treatment in moderate-to-severe psoriasis: a real clinical practice pilot series
International Journal of Dermatology, Vol. 61, Núm. 8, pp. 1029-1033
-
Super-Responders in Moderate-Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives
LIFE-BASEL, Vol. 12, Núm. 9
-
Validation of a Questionnaire to Assess the Perception of Women with Atopic Dermatitis in Family Planning
International journal of environmental research and public health, Vol. 19, Núm. 17
2021
-
104-week safety and effectiveness of dupilumab in the treatment of severe atopic dermatitis. The experience of 5 reference dermatology units in Spain
Anais Brasileiros de Dermatologia, Vol. 96, Núm. 6, pp. 787-790
-
Guselkumab: Mid-term effectiveness, drug survival, and safety in real clinical practice
Dermatologic Therapy, Vol. 34, Núm. 2
-
Risankizumab: A pilot study of short-term effectiveness and safety in real clinical practice
Dermatologic Therapy